Korean J Urol.  1998 Jan;39(1):37-40.

Study of bcl-2 and p53 Protein Expression in Prostatic Cancer

• Jang SH
• Shim BS

Abstract

PURPOSE: bcl-2 and p53 are known to act as a regulator of apoptosis in prostatic cancer and we evaluated the significance of these gene expressions and correlation with prognostic factors in prostatic cancer
MATERIALS AND METHODS
Forty-five formalin-fixed and paraffin-embedded samples of histologically confirmed prostatic cancer, examined using immunohistochemical staining for the two gene products and the expression related to the grade and stage.
RESULTS
We found that positive staining for bel-2 was 46.7%(21/45) and p53 was 31.8%(17/45). As compared to the Gleason grade, positive staining for bel-2 and p53 was 14.3%(2/14), 7.1%(1/14) at low grade, 40.0%(6/15), 40.0% (6/15) at intermediate grade, 81.3%(13/16), 62.5%(10/16) at high grade, respectively. It was significant difference(p<0.05). And, as compared to the stage, positive staining for bel-2 and p53 was 0%(0/7), 0%(0/7) at stage A, 33.3%(4/12), 16.7%(2/12) at stage B, 54.5%(6/11), 45.5%(5/11) at stage C, 73.3%(11/15), 66.7%(10/l5) at stage D, respectively. It was significant difference (p<0.05).
CONCLUSIONS
These results suggest that bcl-2 and p53 expression are associated with the grade and stage of prostatic cancer, and to use them as the prognostic factor of prostatic canecr, further study is needed at the molecular level.

Keyword

Prostatic cancer; bcl-2; p53

MeSH Terms

Apoptosis
Gene Expression
Prostatic Neoplasms*